



NIH AIDS Reagent Program

20301 Century Boulevard
Building 6, Suite 200
Germantown, MD 20874
USA

Phone: 240 686 4740
Fax: 301 515 4015
aidsreagent.org

DATA SHEET

Reagent:	FIV PPR Rev Expression Vector
Catalog Number:	3714
Lot Number:	9/23/97
Release Category:	B
Provided:	1 vial ampicillin-resistant transformed BL21.DE3 (glycerol stock)
Cloning Site:	BamHI/EcoRI cloning site
Cloning Vector:	pRSET B Ampicillin resistant
Description:	An expression vector which produces FIV PPR Rev protein.
Special Characteristics:	<p>cDNA from FIV-PPR was prepared by reverse transcriptase of RNA from PPR-infected cells, and used as a target for PCR. Primers were selected to facilitate directional cloning of Rev into the BamHI-EcoRI sites of the pRSET B expression vector.</p> <p>This clone expresses functional FIV Rev for use in structural, enzymological, and immunological studies. Protein expression is IPTG inducible. The infectious molecular clone FIV-PPR is also available.</p>
Recommended Storage:	Keep the reagent at -80°C or lower. Avoid freeze-thaw cycles as reagent degradation may result.
Contributor:	Dr. John Elder

ALL RECIPIENTS OF THIS MATERIAL MUST COMPLY WITH ALL APPLICABLE BIOLOGICAL, CHEMICAL, AND/OR RADIOCHEMICAL SAFETY STANDARDS INCLUDING SPECIAL PRACTICES, EQUIPMENT, FACILITIES, AND REGULATIONS. NOT FOR USE IN HUMANS.

References: Phillips, T. R., Lamont, C., Konings, D. A., Shacklett, B. L., Hamson, C. A., Luciw, P. A. and Elder, J. H. (1992). Identification of the Rev transactivation and Rev-responsive elements of feline immunodeficiency virus. *J Virol*, 66(9), 5464-71. [PUBMED](#)

Phillips, T. R., Talbott, R. L., Lamont, C., Muir, S., Lovelace, K. and Elder, J. H. (1990). Comparison of two host cell range variants of feline immunodeficiency virus. *J Virol*, 64(10), 4605-13. [PUBMED](#)

NOTE: Acknowledgment for publications should read "The following reagent was obtained through the NIH AIDS Reagent Program, Division of AIDS, NIAID, NIH: FIV PPR Rev Expression Vector from Dr. John Elder (cat# 3714)." Also include the references cited above in any publications.

Last Updated: March 04, 2019

ALL RECIPIENTS OF THIS MATERIAL MUST COMPLY WITH ALL APPLICABLE BIOLOGICAL, CHEMICAL, AND/OR RADIOCHEMICAL SAFETY STANDARDS INCLUDING SPECIAL PRACTICES, EQUIPMENT, FACILITIES, AND REGULATIONS. NOT FOR USE IN HUMANS.